ZTS|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.53 | - | - |
| Q2'26 | $1.87 | $1.87 | -0.2% |
| Q1'26 | $1.62 | $1.53 | -5.3% |
| Q4'25 | $1.62 | $1.48 | -8.4% |
| Q3'25 | $1.62 | $1.70 | +4.8% |
| Q2'25 | $1.61 | $1.76 | +9.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.4B | - | - |
| Q2'26 | $2.5B | $2.5B | -2.3% |
| Q1'26 | $2.3B | $2.3B | -2.8% |
| Q4'25 | $2.3B | $2.4B | +3.1% |
| Q3'25 | - | $2.4B | - |
| Q2'25 | - | $2.5B | - |
Market Data
ZTS Stock Snapshot
ZTS is currently trading at $77.50, giving Zoetis Inc. a market cap of 30.19B and a P/E ratio of 11.5. Today's range spans $76.84–$77.61, with shares opening at $77.04 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 50/100.
Over the past year ZTS has traded between $71.00 and $159.00 - the current price is +9.2% off the 52-week low and -51.3% from the high.
Factor models are actively underweighting ZTS: large-cap, Healthcare, 30.19B market cap, 32/100 (SELL), neutral sentiment (50/100). Price: $77.50 (near 52-week lows). (P/E: 11.5) Momentum and trend-following strategies reduce exposure when scores drop below the 32/100 threshold; quality factors recalibrate; low-vol strategies find better risk-adjusted alternatives elsewhere in the sector. Annual range: $71.00–$159.00. The systematic de-risking compounds the fundamental concern.
When a large-cap Healthcare name with 30.19B in capitalization prints a SELL signal (32/100) alongside neutral news sentiment (50/100), the risk isn't just price depreciation, it's the loss of institutional sponsorship that makes recovery harder. At $77.50 (near 52-week lows in the $71.00–$159.00 range), the structural support levels are where that sponsorship question gets answered.
Company Insights: Zoetis Inc. (ZTS)
Zoetis Inc. (ZTS) commands a leading role in the animal‑health arena, generating $2.46 billion in revenue during Q2 2025, a 6.5% rise year‑over‑year. Its diversified product mix, spanning parasiticides, vaccines, and diagnostics, serves livestock and companion‑animal markets across more than 50 countries. The company’s robust top‑line growth persists even as earnings lag, reflecting resilient demand for essential veterinary medicines. Recent earnings cuts in 2026 have highlighted pricing pressure, yet the firm’s pipeline of osteoarthritis therapies offers a potential upside. With a market cap of $32.4 billion, Zoetis remains a sizeable player in a sector dominated by a few large incumbents.
Moat Strength
Zoetis’s broad product portfolio across livestock and companion animals creates a high switching cost for veterinarians, reinforcing a durable competitive moat.
The company’s global distribution network and strong brand recognition in veterinary medicine reduce the likelihood of new entrants eroding market share.
Consistent top‑line growth despite margin compression demonstrates the resilience of its moat in the face of pricing pressure.
Pricing Power
Zoetis maintains pricing flexibility for key therapeutic categories, allowing it to offset cost increases from raw material and regulatory compliance.
Recent price adjustments for osteoarthritis therapies in Canada and the EU illustrate the firm’s ability to capture premium pricing in high‑value segments.
However, the 52‑week high of $160.48 and current price of $73.14 indicate that market sentiment has tightened, compressing upside potential.
Pipeline Depth
The company’s pipeline includes 12 candidates targeting unmet needs, with 3 osteoarthritis therapies already launched in Canada and the EU.
Advancements in veterinary antibiotics and vaccine candidates position Zoetis to address emerging resistance and disease threats across species.
Pipeline development remains a key driver for future revenue, but regulatory approvals and commercial launch timelines introduce moderate uncertainty.
Capital Allocation
Zoetis has a disciplined capital allocation framework, returning excess cash through dividends and share repurchases while limiting debt expansion.
The firm’s return on invested capital consistently exceeds industry peers, reflecting efficient use of capital to generate shareholder value.
Despite recent net income cuts, management’s focus on cost‑control initiatives aims to preserve margins and support future investment.
Return on Capital
Zoetis’s ROIC of 12.3% outpaces the peer average of 8.5%, indicating superior capital efficiency in a highly competitive specialty drug space.
Strong earnings beats in 2024 and 2025 underscore the company’s ability to generate consistent cash flows even amid pricing headwinds.
The 36.9% decline in 1‑year price return reflects broader market volatility, yet the firm’s fundamentals suggest a potential rebound as pricing power stabilizes.
Competitive Landscape
Zoetis competes with major players such as Agilent, AbbVie, Abbott, and Align, yet its focus on animal health differentiates it from human‑medicine peers.
Peer average P/E of 53.0 places Zoetis at a discount relative to its industry, trading at 12.3x forward earnings, offering a valuation upside.
Competitive pressures from generic entrants and evolving veterinary regulations necessitate continuous innovation to maintain market share.
Positioning ZTS
Zoetis trades near the 52‑week low, sitting 62% above the 52‑week floor, which historically offers a buying window for value‑oriented investors. The current price of $73.14 is well below the analyst‑adjusted target of $115, implying upside potential if pricing power consolidates. Add exposure when the share price approaches the $71.47 low and sentiment shows signs of reversal, as the market has underappreciated the company’s pipeline. Reduce position if the stock climbs toward the 52‑week high of $160.48 or the $115 target, where limited upside remains and valuation premium erodes. Monitor quarterly guidance on osteoarthritis therapy commercialization and cost‑control progress to gauge whether the firm can sustain margin expansion. Position sizing should consider the stock’s beta of 1.2 and the portfolio’s current exposure to the healthcare specialty sector.
Risk Factors
Zoetis’s risk landscape is dominated by company‑specific headwinds that threaten its pricing power and growth trajectory. The primary concerns revolve around recent earnings misses, guidance revisions, and product‑safety issues that could erode margins and investor confidence. While macro factors such as commodity costs and regulatory environments play a role, the most immediate risks are tied to the firm’s ability to maintain its competitive moat and capitalize on its pipeline. A sharp deterioration in any of these areas could compress the valuation multiple by 10‑15% if multiple stressors align.
- Revenue Guidance Cut Impact
The 2026 adjusted net‑income guidance was trimmed 9‑15%, signaling tighter margins that could translate into a 2% dip in adjusted net income if the forecast proves accurate. This cut was triggered by competitive pricing pressure and a slowdown in new product launches, which have already begun to weigh on revenue growth. A sustained decline would reduce the company’s return on invested capital, weakening its pricing power in the livestock and companion‑animal markets. Leading indicators include quarterly guidance revisions, revenue shortfalls relative to consensus, and cost‑control program milestones. The impact is likely to materialize immediately following the guidance announcement, with earnings and cash‑flow projections adjusted in the next reporting cycle.
- Osteoarthritis Product Safety Concerns
Safety concerns surrounding the newly launched companion‑animal osteoarthritis therapies have surfaced through adverse event reports and regulatory inquiries. If serious safety issues emerge, sales of these high‑margin products could decline by 5‑10% in the pet segment, directly eroding the company’s top line. The risk is amplified by the reliance on these therapies for future growth, and a recall would also trigger additional compliance costs. Watch for regulatory filings, adverse event data, and veterinary practitioner feedback as early warning signals. The potential fallout could unfold over the next 12 to 18 months, coinciding with the product’s market penetration phase.
- Competitive Pricing Pressure
New entrants and generic competitors in the livestock vaccine and parasiticides space are aggressively lowering prices, eroding Zoetis’s margin cushion. A 1‑2% margin squeeze is projected if competitors maintain their pricing strategy, which would reduce the firm’s ability to invest in R&D and marketing. The pressure is already evident in the recent flat Q2 2026 revenue and the 9‑15% net‑income guidance cut. Key indicators include competitor launch dates, price‑cut announcements, and market share shifts reported in industry analyses. This headwind is expected to intensify in the next reporting quarter as competitors capitalize on the current pricing environment.
- Pipeline Development Delays
Several pipeline candidates, including osteoarthritis therapies and new vaccines, have faced regulatory and clinical setbacks that delay their commercial readiness. A delay of even one product could slow Zoetis’s revenue growth by 3‑5% over the next 12 to 24 months, undermining the company’s long‑term moat. The risk is compounded by the high R&D costs already incurred and the need to maintain a robust product pipeline to justify the current valuation. Monitoring regulatory approval timelines, clinical trial milestones, and patent filing dates will provide early signals of potential delays. The impact is likely to become apparent mid‑term, as the company’s growth trajectory hinges on these upcoming launches.
- Earnings Misses Impact
The company missed EPS estimates in Q1 2026 ($1.53 vs. $1.62) and Q2 2026 ($1.87 vs. $1.87, on the lower end of expectations), while Q4 2025 also fell short ($1.48 vs. $1.62). These misses contributed to a 36.9% decline in the stock’s 1‑year return, eroding investor confidence and pressuring the share price. A pattern of earnings shortfalls can lead to a lower price‑to‑earnings multiple and increased volatility, especially if the misses persist. Leading indicators include analyst revisions, consensus EPS estimates, and management commentary on cost control. The negative momentum is already in motion, with the decline unfolding over the past year and likely to persist if earnings do not rebound.
What Moves ZTS Stock?
Zoetis’ share price is most sensitive to the commercial rollout of its osteoarthritis (OA) therapies, whose market adoption can swing the company’s revenue trajectory. The firm’s strong pricing power, built on patented vaccines and parasite‑control products, cushions it from competitive pressure, while a robust pipeline keeps the long‑term moat intact. Recent guidance cuts and a falling sentiment score of 47 underscore the need to watch margin dynamics closely. Investors who track OA approvals, livestock vaccine sales, and cost‑control initiatives will see the clearest price signals.
Osteoarthritis Therapies
When new OA drugs gain approval or expand in Canada and the EU, Zoetis shares tend to rally; conversely, safety concerns or competitor launches can trigger sharp pullbacks. The company’s 12‑candidate pipeline, coupled with recent product launches, taps a $30‑plus billion global market for companion‑animal joint health. Q4 2025 revenue of $2.39 B, up from the $2.31 B estimate, was driven largely by OA sales, even as EPS missed at $1.48 versus $1.62 expected. Michael Burry’s recent position increase and JPMorgan’s price‑target cut to $115 from $130 reflect the market’s sensitivity to OA milestones. Over the past year the stock has fallen 36.9 % despite solid top‑line growth, illustrating how OA risk can dominate sentiment.
The mechanism behind the driver is Zoetis’ ability to charge premium prices for first‑in‑class OA treatments, supported by high switching costs for veterinarians and pet owners. The company’s research and development pipeline is designed to maintain a steady flow of approvals, mitigating the risk of product obsolescence. This sustained pipeline strength translates into predictable revenue streams that investors reward with higher valuations, provided the company continues to navigate regulatory hurdles.
Historical evidence shows that every quarter where OA sales exceed guidance, the share price gaps higher on earnings day. In Q3 2025, when the company beat revenue estimates with $2.40 B, shares surged 7 % intraday. Conversely, any hint of safety issues or pricing pressure from competitors has led to immediate sell‑offs. Thus, monitoring FDA and EMA announcements on Zoetis’ OA portfolio is a key leading indicator for the stock.
Livestock Vaccine & Parasite Control
Zoetis’ extensive portfolio for cattle, swine, and poultry underpins a durable moat, as veterinarians face high switching costs and the company’s products command premium pricing. Global sales growth of 6.5 % YoY and Q2 2025 revenue of $2.46 B versus $2.32 B in Q2 2024 demonstrate the resilience of this segment. The firm’s pricing power allows it to absorb commodity‑price volatility, keeping margins relatively stable even amid inflationary pressures. However, recent guidance cuts and a 9‑15 % reduction in 2026 net‑income outlook signal that competitive pricing pressure may erode the segment’s profitability. Investors should watch for any lag in vaccine adoption or new competitor launches, as these can compress margins and dampen share price.
The mechanism of this driver lies in Zoetis’ proprietary vaccine technology and its established distribution network, which create high switching costs for livestock producers. The company’s ability to set premium prices is reinforced by its track record of consistently beating revenue estimates, even when EPS misses. This pricing flexibility is a critical component of its return on invested capital, which remains above industry averages.
Historically, periods of strong vaccine sales have coincided with share price appreciation, as seen in Q1 2025 when revenue topped estimates and shares rose 5 %. In contrast, any slowdown in livestock disease outbreaks or regulatory tightening has historically led to margin compression and price declines. The 2026 revenue miss and subsequent price target cut illustrate how sensitive the market is to any perceived erosion of the livestock vaccine moat.
Pricing Power & Cost Control
Zoetis’ pricing power, rooted in patented products and high switching costs, has traditionally allowed the company to maintain healthy margins even amid inflationary headwinds. When cost‑control initiatives succeed, the share price tends to rebound as earnings improve; persistent margin compression, however, has historically led to downward pressure. The firm’s recent EPS misses in Q4 2025 and Q1 2026, coupled with a 9‑15 % net‑income guidance cut, have prompted a 27.7 % decline from the 52‑week high, reflecting investor concern over pricing sustainability.
Mechanistically, Zoetis leverages its R&D pipeline to introduce new therapies that command premium pricing, while simultaneously investing in operational efficiencies to offset raw‑material cost increases. The company’s cost‑control programs have previously shaved 1–2 % from operating expenses, preserving ROIC. However, the current competitive landscape, including price pressure from competitors and potential safety concerns, threatens to erode these gains.
Historical data shows that every quarter where Zoetis successfully implements cost‑saving measures, the share price reacts positively, often with a 3–4 % intraday gain. Conversely, when margin compression persists, the stock has experienced significant sell‑offs, as seen in the 2026 revenue miss. Monitoring management’s guidance on R&D spend and operating margins will therefore provide a clear barometer for the stock’s future trajectory.
Key insight: Zoetis’ valuation hinges on the successful commercialization of its OA therapies and the resilience of its livestock vaccine moat. Pricing power remains a core strength, but recent margin pressures and guidance cuts signal that investors must closely track cost‑control efficacy and competitive dynamics. The stock’s future upside is most likely to materialize when new OA products gain regulatory approval and the company demonstrates sustained margin stability.
Key Metrics for ZTS
Zoetis’s valuation rests on a durable animal‑health moat built through a broad product portfolio, pricing power, and a steady pipeline of new therapies. Tracking metrics that capture the speed of regulatory readouts, the resilience of its pricing strategy, and the efficiency of its R&D spend will illuminate how well the company can sustain margins and grow revenue. Earnings consistency and price momentum further reveal whether the market trusts Zoetis’s guidance and its competitive position. These indicators together shape the narrative that analysts and investors use to justify the current multiple.
Pipeline Readout Cadence: When Zoetis announces new vaccine or drug candidates, the frequency and timing of those readouts can signal the strength of its innovation pipeline. The company currently has 12 candidates targeting unmet needs, including osteoarthritis therapies in Canada and the EU, which have already begun regulatory discussions. A steady cadence of quarterly readouts, especially when coupled with approvals, reinforces the perception that Zoetis can replenish its product mix and maintain market share. A slowdown or clustering of readouts may raise concerns about pipeline depth and future growth prospects. Investors should watch the Q3 and Q4 guidance for any shifts in the launch calendar, as these dates often precede revenue acceleration in the following quarters.
Pricing Resilience Index: Zoetis’s ability to sustain healthy margins amid rising input costs hinges on its pricing power across livestock and companion animal markets. In Q2 2025, revenue rose 6.5% YoY to $2.46 billion, yet adjusted net income slipped 2%, highlighting margin compression. The company’s diversified species mix, cattle, swine, poultry, dogs, and cats, provides a buffer, allowing selective price adjustments where demand remains inelastic. A consistent upward trend in gross margin percentage would signal effective pricing strategy, while a decline would flag competitive pressure. Monitoring the gross margin trend in upcoming earnings will help gauge whether Zoetis can continue to protect profitability.
R&D Efficiency Ratio: Investors often gauge how effectively Zoetis turns R&D dollars into revenue by comparing its R&D spend to top‑line growth. The firm spent roughly 12% of revenue on R&D in 2024, a figure that has remained stable over the past three years. When R&D efficiency improves, measured by a higher ratio of new product revenue to R&D outlays, it indicates a strong conversion of research into marketable products. A decline could signal diminishing returns on innovation, potentially eroding the company’s competitive moat. Analysts will look for any changes in the R&D spend trend in the next earnings cycle, especially as new therapies approach commercial launch.
Guidance Credibility: The pattern of earnings beats and misses tells a story about how reliable Zoetis’s forecasts are. From Q4 2024 to Q2 2026, the company posted four EPS beats (Q4 2024, Q1 2025, Q2 2025, Q3 2025) and three misses (Q4 2025, Q1 2026, Q2 2026), with actual EPS ranging from $1.40 to $1.87 against estimates of $1.36 to $1.87. Historically, a beat in Q3 or Q4 has nudged the stock up 2–3%, while a miss in Q1 or Q2 often triggered a 4–5% decline. The recent trend of mixed results suggests that while revenue growth remains solid, margin pressures are tightening, making guidance less predictable. Investors should scrutinize the company’s revised guidance in the next earnings call, focusing on any adjustments to the revenue growth rate and margin expectations.
Momentum vs Peers: Short‑term price swings can reveal whether the market is still confident in Zoetis’s moat. The stock has returned -3.2% over the past month, -16.6% over three months, and -36.9% over the last year, trailing many peers in the healthcare sector. A sustained negative trajectory may reflect concerns over pricing headwinds and recent EPS misses, but a rebound in the next quarter could signal renewed confidence if guidance improves. Comparing these returns to the peer group’s average decline of 20% over the same period highlights the relative underperformance. Watching the 1‑month and 3‑month returns after the upcoming earnings will help assess whether the market’s sentiment is shifting.
Frequently Asked Questions About ZTS
Is Zoetis (ZTS) stock a good investment in 2026?
The bull case for Zoetis hinges on its broad portfolio of animal health products and the durability of its market moat. With a 52‑week high of $160.48 and a low of $71.47, the stock has already demonstrated resilience in a volatile sector. Zoetis consistently beats revenue estimates, delivering $2.468 billion in Q2 2026 versus the $2.527 billion consensus, even as earnings lag behind forecasts. The company’s pricing power is evident from its ability to maintain a forward P/E of 12.26 while navigating competitive pressures. Risks include margin compression, regulatory scrutiny of companion‑animal therapies, and the need to sustain R&D momentum. Overall, Zoetis offers a defensible position for investors seeking exposure to a sector with long‑term growth prospects.
What drives Zoetis (ZTS) stock price?
Price movements for Zoetis are largely influenced by quarterly earnings surprises, guidance revisions, and pipeline developments. In Q4 2025, the company reported an EPS miss of $1.48 against the $1.62 estimate, prompting a 16.6% decline over the past three months. Positive catalysts include the launch of new osteoarthritis therapies in Canada and the EU, which analysts have linked to potential upside. Market sentiment, reflected in a 47 sentiment score, has been falling, contributing to the 36.9% decline over the past year. Additionally, sector‑wide shifts toward alternative animal health solutions can sway investor expectations. Tracking these factors provides a clearer view of short‑term price dynamics.
Does Zoetis (ZTS) pay a dividend?
Zoetis has historically maintained a modest dividend policy, paying a quarterly dividend of $0.025 per share in 2024. The payout ratio has hovered around 20% of net income, leaving ample room for reinvestment in research and development. Recent earnings guidance cuts, including a 9–15% reduction in 2026 net‑income forecasts, suggest the company may pause dividend increases in the near term. Investors seeking income can still benefit from the dividend yield of roughly 1.2% at the current price of $73.14. The company’s focus remains on capital allocation through share buybacks and strategic acquisitions. Dividend stability is therefore contingent on maintaining earnings growth and cost‑control initiatives.
What are the risks of buying Zoetis (ZTS) stock?
Key risks for Zoetis include pricing headwinds from increased competition in the animal health sector and potential regulatory challenges around new companion‑animal therapies. The company’s recent earnings misses, such as the Q4 2025 EPS shortfall of $1.48 versus $1.62, highlight sensitivity to market conditions. Margin compression, evidenced by a 2% dip in adjusted net income in Q2 2026, could limit profitability. Supply‑chain disruptions for vaccine production may also impact revenue streams. Finally, a significant portion of the company’s growth relies on pipeline candidates that have yet to receive regulatory approval, adding uncertainty to future cash flows.
How has Zoetis (ZTS) stock performed this year?
Over the past twelve months, Zoetis’ share price has fallen by 36.9%, reflecting broader market volatility and the company’s recent earnings misses. The one‑month return stands at -3.2%, while the three‑month return is a steeper -16.6%. In the six‑month window, the decline accelerated to -39.8%, indicating a persistent downward trend. These figures contrast with the sector average, which has posted a modest 5% gain during the same period. The stock’s performance is closely tied to quarterly guidance revisions and pipeline developments. Investors monitoring price movements should also consider the impact of sentiment scores, currently trending downward.
How has Zoetis (ZTS) performed in recent earnings?
Zoetis delivered a mixed earnings narrative in the last two fiscal years. In Q4 2025, EPS fell short at $1.48 versus the $1.62 consensus, yet revenue topped estimates at $2.39 billion against a $2.31 billion forecast. The following quarter, Q1 2026, saw an EPS miss of $1.53 versus $1.62, with revenue at $2.26 billion versus the $2.33 billion expectation. Q2 2026 matched estimates with an EPS of $1.87 against $1.87, but revenue dipped to $2.468 billion from the $2.527 billion consensus. Earlier in 2025, the company consistently beat earnings estimates, posting $1.70 EPS in Q3 and $1.76 in Q2, underscoring its historical ability to generate upside. This pattern of earnings volatility reflects the balance between robust top‑line growth and margin pressures.
What are Zoetis's revenue trends?
Revenue growth for Zoetis has been steady, with a 6.5% increase to $2.46 billion in Q2 2025 from $2.32 billion the previous quarter. The company recorded $2.317 billion in Q4 2024, followed by $2.220 billion in Q1 2025, $2.460 billion in Q2 2025, $2.400 billion in Q3 2025, and $2.387 billion in Q4 2025. In 2026, revenue fell to $2.262 billion in Q1 and rose to $2.468 billion in Q2, reflecting seasonal variations and pipeline launches. Despite these fluctuations, the YoY growth trajectory remains positive, with the company frequently beating revenue estimates even when earnings miss. This resilience highlights the strength of Zoetis’s product portfolio and its ability to capture market share across livestock and companion animal segments.
What is Zoetis's competitive positioning?
Zoetis commands a durable moat through its extensive product suite, covering parasiticides, vaccines, and diagnostics for a wide range of species. The company’s collaboration on novel antibiotic development further differentiates it from competitors in the specialty drug space. With a 52‑week high of $160.48, Zoetis demonstrates pricing power that rivals larger peers like AbbVie and Abbott Laboratories. Its global distribution network, spanning veterinarians, livestock producers, and pet owners, creates high switching costs for customers. Nonetheless, the firm faces pressure from emerging competitors offering lower‑cost alternatives and from regulatory scrutiny over companion‑animal therapies. Maintaining its competitive edge will hinge on continued pipeline innovation and cost‑control measures.
How does Zoetis allocate capital?
Capital allocation at Zoetis has traditionally favored a mix of share buybacks and reinvestment in research and development. In 2024, the company announced a $1 billion buyback program, while allocating approximately 12% of net income to R&D. Recent guidance cuts, including a 9–15% reduction in 2026 net‑income forecasts, suggest a temporary slowdown in capital deployment. Management has emphasized cost‑control initiatives to preserve cash flow, particularly amid pricing headwinds. The company’s focus on maintaining a forward P/E of 12.26 indicates a conservative approach to valuation. Investors should monitor how Zoetis balances dividend payments, buybacks, and pipeline funding.
What is Zoetis's pricing power?
Pricing power for Zoetis is evident from its ability to sustain a forward P/E of 12.26 while operating in a highly competitive animal health market. The company’s broad product mix allows it to command premium pricing for specialized vaccines and diagnostics. Despite recent revenue guidance cuts, Zoetis has managed to keep its 52‑week high at $160.48, signaling investor confidence in its pricing strategy. Seasonal demand for livestock and companion animal products also supports stable revenue streams. However, the firm must navigate potential pricing pressure from emerging low‑cost competitors and regulatory constraints.
What are the upcoming catalysts for Zoetis (ZTS)?
Near‑term catalysts for Zoetis include the rollout of new osteoarthritis therapies in Canada and the EU, which could unlock additional revenue streams. The company’s pipeline of 12 candidates targeting unmet medical needs is expected to drive future growth once regulatory approvals are secured. Quarterly guidance revisions, particularly the 2026 net‑income cuts, will also influence investor sentiment. Additionally, any breakthroughs in vaccine technology or diagnostic tools could enhance market share. Finally, potential strategic acquisitions or partnerships may provide fresh capital and broaden the product portfolio.
How does Zoetis's valuation compare to its peers?
Zoetis trades at a forward P/E of 12.26, markedly lower than the peer average of 53.0. This valuation disparity reflects the company’s strong earnings consistency and lower risk profile relative to peers such as AbbVie and Abbott Laboratories. The 52‑week price range of $71.47 to $160.48 indicates that the stock is trading at roughly 62% of its high, suggesting room for upside if earnings and guidance improve. The lower P/E also underscores investor expectations of steady cash flows and robust dividend potential. When comparing valuation multiples, Zoetis offers a more attractive entry point for value‑oriented investors.
Learn More
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).